---
title: "Telix Pharma CFO Darren Charlton Smith acquires 2,071 common shares for AUD 19,999.58"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298970130.md"
description: "Telix Pharmaceuticals CFO Darren Charlton Smith purchased 2,071 common shares for AUD 19,999.58 at a price of AUD 9.66 per share. This transaction increased his direct holding of ordinary shares to 13,992."
datetime: "2026-09-14T23:20:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298970130.md)
  - [en](https://longbridge.com/en/news/298970130.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298970130.md)
generator: "portal-rs"
---

# Telix Pharma CFO Darren Charlton Smith acquires 2,071 common shares for AUD 19,999.58

-   Telix Pharmaceuticals: Group Chief Financial Officer Darren Charlton Smith increased his stake via a purchase of 2,071 ordinary shares. \* Deal price was AUD 9.66 per share. \* Directly held ordinary shares rose to 13,992. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-061944), on September 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [TLX.US](https://longbridge.com/en/quote/TLX.US.md)
- [TLX.AU](https://longbridge.com/en/quote/TLX.AU.md)

## Related News & Research

- [Canaccord Genuity Keeps Their Buy Rating on Telix Pharmaceuticals (TLPPF)](https://longbridge.com/en/news/300886940.md)
- [Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging](https://longbridge.com/en/news/300495723.md)
- [IBA agrees to distribute Telix unit ARTMS’ QUANTM solid-target cyclotron technology worldwide](https://longbridge.com/en/news/300644879.md)
- [Telix wins FDA Fast Track for BiPASS pre-biopsy prostate cancer imaging study](https://longbridge.com/en/news/300489191.md)
- [Telix Pharmaceuticals announces shareholder meeting](https://longbridge.com/en/news/299579547.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**